Bio Sequence

The Competitive Landscape Behind the FDA-approved New Treatment for Biliary Tract Cancer, Keytruda

6 November 2023
3 min read

On November 1st, the United States Food and Drug Administration (FDA) granted approval to the antineoplastic monoclonal antibody drug Keytruda, produced by Merck, for use combined with chemotherapy in treating locally advanced unresectable or metastatic biliary tract cancer. Trial results showed significant improvement in patients' overall survival rates. This marks the anti-cancer drug Keytruda’s sixth indication in the area of gastrointestinal cancer.

Biliary tract cancer is a rare but highly malignant disease, with most patients losing their surgical opportunity by the time of diagnosis. Treatment options are very limited, hence, when the disease progresses, there is an urgent need for new therapy options. The trial results showing significant improvement in patients' overall survival time is indeed a major breakthrough, offering new hope for patients who have lost their surgical opportunity or whose disease has reached an advanced stage.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Source, Patsnap Bio

A Panoramic View of Keytruda’s Top 10 Patent Assignees

According to the Patsnap Bio Sequence Database, the top 10 applicants for the Keytruda patent are Novartis AG with 438 applications, Merck Sharp & Dohme Corp. with 350 applications, and Merck Sharp & Dohme LLC with 299 applications. For more applicants, please refer to the image below.

图形用户界面, 应用程序

描述已自动生成

Source, Patsnap Bio

Evolution of the Layout of Top 10 Patent Assignees over the years, the Competitive landscape over time

Exploring the changes occurring within the application structure amongst Keytruda's top 10 patent assignees over time delivers insights into the competitive landscape's evolution.

Source, Patsnap Bio

How Can You Acquire Comprehensive Information on Aflibercept Sequence Patents for Free?

Firstly, establish a free account with Patsnap Bio Sequence Database. Proceed to the homepage's "standard search" and enter the Keytruda sequence or directly input the drug name, Keytruda, in the "Drug/Gene index. This single action will unravel extensive details of keytruda 's sequence, patent, literature, data from diversified sources, and a visually competitive landscape of patents.

图形用户界面, 应用程序

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The left panel's search result details page is equipped with an exhaustive range of filters, enabling you to pinpoint specific data accurately, thereby boosting your search experience and overall efficiency. Clicking on each data point will unfold a rich and detailed data set and a host of advantageous and practical tools to support your research process.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

It is important to note that Patsnap Bio is the most extensive sequence search platform for the Patsnap database. It incorporates AI with human-curated data for comprehensive handling of protein and nucleotide sequence data plucked from global patents, biological periodicals, and public repositories. Essential biological sequences are manually annotated, illuminating structural modifications to provide the most accurate sequence data and boost sequence retrieval efficiency.

Free registration is available for the Bio biological sequence database: https://bio.patsnap.com. Act now to expedite your sequence search tasks.

SparX Biopharma declares FDA approval of IND application for SPX-303, an initial human test of anti-LILRB2/PD-L1 antibody medication
Latest Hotspot
3 min read
SparX Biopharma declares FDA approval of IND application for SPX-303, an initial human test of anti-LILRB2/PD-L1 antibody medication
6 November 2023
SparX Biopharmaceutical Corp. happily announces FDA approval of its IND application for SPX-303, a key development in powered antibody therapies and a leading anti-LILRB2/PD-L1 bispecific antibody drug candidate.
Read →
Analysis on the Research Progress of Dihydrofolate Reductase Inhibitor
Analysis on the Research Progress of Dihydrofolate Reductase Inhibitor
6 November 2023
DHFR, or dihydrofolate reductase, is an indispensable enzyme required for the survival of most prokaryotic and eukaryotic cells as it is involved in the biosynthesis of essential cellular components.
Read →
A Comprehensive Review of Nepafenac's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Nepafenac's R&D Innovations and Drug Target Mechanism
10 November 2023
This article summarized the latest R&D progress of Nepafenac, the Mechanism of Action for Nepafenac, and the drug target R&D trends for Nepafenac.
Read →
Pharmaceutical Insights: Nemolizumab's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Nemolizumab's R&D Progress and its Mechanism of Action on Drug Target
10 November 2023
This article summarized the latest R&D progress of Nemolizumab, the Mechanism of Action for Nemolizumab, and the drug target R&D trends for Nemolizumab.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.